This company listing is no longer active
7H7 Stock Overview
A multidisciplinary integrative wellness company, provides evidence-based alternative medicines and novel psychedelic therapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Levitee Labs Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.0005 |
| 52 Week High | CA$0.033 |
| 52 Week Low | CA$0.0005 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -95.24% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -99.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7H7 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.2% | -0.02% |
| 1Y | -95.2% | -20.1% | 8.2% |
Return vs Industry: 7H7 underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 7H7 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 7H7 volatility | |
|---|---|
| 7H7 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 7H7 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 7H7's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | n/a | David Bentil | www.leviteelabs.com |
Levitee Labs Inc., a multidisciplinary integrative wellness company, provides evidence-based alternative medicines and novel psychedelic therapies. The company operates through two segments, Medical Services and Selling Products. It offers treatments and medications for substance use disorders and chronic pain, such as myofascial pain, fibromyalgia, neuropathy, and chronic regional pain syndrome, as well as hepatitis-C and mental health conditions.
Levitee Labs Inc. Fundamentals Summary
| 7H7 fundamental statistics | |
|---|---|
| Market cap | €364.91k |
| Earnings (TTM) | €0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs 7H7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7H7 income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €0 |
| Earnings | €0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 7H7 perform over the long term?
See historical performance and comparison